The Canadian Association for the Study of the Liver (CASL) stands in strong support of the American Association for the Study of Liver Diseases (AASLD) and its partner organizations in the importance of universal HBV vaccination at birth as a proven, lifesaving measure that prevents chronic hepatitis B infection, liver disease, and liver cancer. Rolling back this policy risks widening gaps in prevention and disproportionately impacts vulnerable communities. CASL reaffirms its commitment to evidence-based practices and the global goal of eliminating viral hepatitis by 2030.
We stand with AASLD and its partners in reaffirming the universal birth dose as an essential component of hepatitis B prevention and public health.
English 
French